KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
140 patients (estimated)
Sponsors
Keros Therapeutics, Inc.
Tags
Growth Factor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1646
NCT Identifier
NCT04419649

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.